Answers are grounded in this paper and cite their sources.
This analysis highlights the rising concerns of bloodstream infections and complications from vascular access, particularly peripheral intravenous catheters.
I would like to bring attention to a potentially overlooked issue within the critical care community, prompted by an Adult CCRN Review Question in the Certification Test Prep column in the April 2025 issue of Critical Care Nurse.1 The question reads as follows: The correct answer was B, and the rationale was as follows: This question presents a clinical challenge, as the patient is arguably at risk for all the listed complications. The rationale provided for the correct answer—deep vein thrombosis—raises important concerns. Deep vein thrombosis is a well-documented complication in critically ill patients, particularly those with malignancies such as gastric adenocarcinoma, but the rationale dismisses the risk of vascular infection due to the absence of a central venous catheter (CVC). This assumption warrants closer examination.Key clinical considerations not addressed include the following: The rationale states that a "catheter-associated infection is unlikely in the absence of a central venous catheter." However, this perspective is increasingly outdated. Recent literature demonstrates that peripheral intravenous (PIV) catheters are a significant source of bloodstream infections (BSIs), and in some cases, bacteremia may occur before a CVC is placed.Peripheral intravenous therapy is associated with a high complication rate, occurring in 35% to 50% of cases, and poses significant risks to hospitalized patients.2 These complications include phlebitis, infiltration, vascular damage, and infection, which may escalate to systemic inflammatory response syndrome, sepsis, septic shock, and even death.In a mixed-methods study conducted in a surgical oncology ward, Santos-Costa et al2 identified substantial deviations from evidence-based PIV practices, including improper skin preparation, inconsistent aseptic techniques, inadequate hub scrubbing, and poor dressing application and securement. Oncology patients are particularly vulnerable due to the vascular toxicity of antineoplastic agents, which impair endothelial function and immune response.In 2022, Urbanovsky3 found that in 13 methicillin-resistant Staphylococcus aureus bacteremia events, more than 46% were linked to the use of a PIV catheter. Additionally, Massey et al4 noted that one-third of adult patients receiving a PIV experience complications, including BSIs. Their survey showed a lack of nursing knowledge regarding the appropriate length of time for hub scrubbing (68%), the correct solution for hub scrubbing (67%), and the length of time a PIV catheter may remain in place (71%). Despite these knowledge gaps, the authors noted that nurses often appear confident in their assessment, management, and removal of PIV catheters.4Mannari and Soni5 highlighted that complications such as BSIs from PIV catheters tend to increase with longer dwell times. Many studies point to poor nursing compliance with best practice guidelines, contributing to a decline in the quality of PIV catheter care.5 Peripheral intravenous catheters have a failure rate exceeding 50% before the completion of therapy—due to issues such as phlebitis, occlusion, and leakage—which often results in premature removal, repeated insertions, and delays in treatment.Marsh and colleagues6 found that studies often did not define catheter-associated BSIs, and other studies used clinical findings without specific culture data.Drugeon et al7 noted that more than 90% of hospitalized patients receive a PIV catheter. Of the more than 2 billion devices placed annually worldwide, nearly 50% are associated with complications or failure. In a 27-month retrospective study of nearly 10 000 patients, 25 cases of PIV-BSI were found—many originating in the emergency department. All cases involved vascular complications or severe sequelae, such as sepsis, endocarditis, and abscess formation. The causative organism in all cases was S aureus.Zanella et al8 analyzed nearly 180 000 patients and identified 249 catheter-associated infections—90 attributed to PIV catheters and 94 to short-term CVCs. The authors advocated for enhanced surveillance of PIV-related BSIs. Hogle and colleagues9 found that hospitals often overlook non–central catheter-associated BSIs due to surveillance protocols focused solely on CVCs. In their study, PIVs accounted for more than one-third of hospital-acquired BSIs.Alicdan et al10 reported that PIVs with dwell times exceeding 96 hours were more than 5 times more likely to be associated with hospital-onset bacteremia. They found that the incidence of PIV-BSI and central catheter–associated bloodstream infection outside of the intensive care unit were similar; however, the risk of the causative microbe being S aureus was higher in PIV cases. Their findings support the inclusion of PIV catheters in infection surveillance programs.These findings collectively challenge the notion that peripheral access is inherently low risk. As such, the critical care community must reconsider how to assess and mitigate infection risks associated with all vascular access devices—not just central catheters.Although deep venous thrombosis is a valid concern in the clinical scenario presented in the Adult CCRN Question, the rationale for the exclusion of vascular infection risk due to the absence of a central catheter is misleading. The critical care community must update educational materials and clinical guidelines to reflect the evolving understanding of PIV-related complications. Comprehensive infection prevention strategies must encompass all vascular access devices—not just central catheters—to ensure optimal patient safety.
No takes yet. Share an insight, caveat, or question.
Tammy L. Monter (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: